Helix Biopharma Corp (HBPCF) 1.3034 $HBPCF Helix

New Post Public Reply Private Reply Replies (0) Message Board

Jun 14, 2016 at 8:01 PM

Helix Biopharma Corp (HBPCF) 1.3034 $HBPCF

Helix BioPharma Corp. Appoints Evolution Life Science Partners as Advisors
Marketwired - Thu Jun 02, 7:00AM CDT
AURORA, ON--(Marketwired - Jun 2, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Evolution Life Science Partners to act as advisors to the Company. Activities the Company may pursue could include, but are not limited to, partnering or other collaboration agreements. The Company does not intend to disclose developments with respect to this process except as required under applicable securities regulations.
HBP: 5.41 (-0.04), HBP.TO: 1.99 (+0.14)

First Patient Dosed in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer
Marketwire Canada - Wed May 11, 6:30AM CDT
AURORA, ON--(Marketwired - May 11, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the first patient was dosed in the Phase II component of study LDOS002.
HBP: 5.41 (-0.04), HBP.TO: 1.99 (+0.14)

Helix BioPharma Corp. Subsidiary, Helix Polska Sp zo.o., Qualifies for CAD4.1 Million Grant From the Polish National Center for Research and Development
Marketwire Canada - Mon May 09, 6:30AM CDT
AURORA, ON--(Marketwired - May 9, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its wholly owned subsidiary, Helix Polska Sp. z o.o. qualifies for a grant of approximately PLN12.5mil from the Polish National Centre for Research and Development to develop V-DOS47 in breast cancer. The acceptance of the grant is subject to review and approval of the final terms and conditions by Helix's management and Board of Directors and may be subject to conditions imposed by the granting authority and corporate or other approvals.
HBP: 5.41 (-0.04), HBP.TO: 1.99 (+0.14)

Helix BioPharma Corp. Closes CAD4.7 Million Private Placement Financing
Marketwired - Fri Apr 29, 6:30AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD4.7 million.
HBP: 5.41 (-0.04), HBP.TO: 1.99 (+0.14)

First Patient Enrolled in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer
Marketwire Canada - Thu Apr 28, 6:30AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the first patient has been enrolled in the Phase II component of study LDOS002.
HBP: 5.41 (-0.04), HBP.TO: 1.99 (+0.14)

Trial Steering Committee Recommends Initiation of Phase II L-DOS47 Study in Non-Small Cell Lung Cancer
Marketwire Canada - Thu Apr 21, 4:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the recommendation by the Trial Steering Committee to initiate the Phase II component of the LDOS002 study.
HBP: 5.41 (-0.04), HBP.TO: 1.99 (+0.14)

Helix BioPharma Corp. Announces Important Additions to Its Leadership Team
Marketwire Canada - Wed Apr 20, 6:30PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Dr. Patrick Frankham to Chief Operating Officer and the promotion of Mr. Steve Demas to the position of Chief Medical Officer. Dr. Frankham and Mr. Demas will both report directly to Dr. Sven Rohmann, Helix's newly appointed Chief Executive Officer.
HBP: 5.41 (-0.04), HBP.TO: 1.99 (+0.14)

Helix Biopharma Corp. Announces the Receipt of Subscription Agreements Totalling CAD4.7 Million for Private Placement Financing
Marketwire Canada - Fri Apr 15, 6:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for units for aggregate gross proceeds of approximately CAD4.7 million.
HBP: 5.41 (-0.04), HBP.TO: 1.99 (+0.14)

Helix BioPharma Corp. Announces CEO Change
Marketwire Canada - Tue Mar 29, 3:46PM CDT
Helix BioPharma Corp. (hereinafter defined as "Helix" or the "Company"

(TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, announces that Dr. Zbigniew Markowski will be stepping down, for personal and family reasons, from his positions as Chief Executive Officer of Helix BioPharma Corp and Chairman of Helix Polska, effective March 29th, 2016. Stepping into both roles, effective immediately, will be Dr. Sven Rohmann.
HBP: 5.41 (-0.04), HBP.TO: 1.99 (+0.14)

Helix Biopharma Corp. Announces Second Quarter Fiscal 2016 Results
Marketwire Canada - Wed Mar 16, 3:15PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the second quarter of fiscal 2016, ended January 31, 2016.
HBP: 5.41 (-0.04), HBP.TO: 1.99 (+0.14)

Helix BioPharma Corp. Reports on Advancement of Its L-DOS47 Phase I/II Study in Poland
Marketwire Canada - Tue Mar 08, 7:18PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Registration Office of Medicinal Products, Medical Devices and Biocides in Poland and the Bioethics Committee has approved an amendment to the Phase I/II study ("LDOS002"

defining the dose and dosing regimen for the Phase II study.
HBP: 5.41 (-0.04), HBP.TO: 1.99 (+0.14)

Helix BioPharma Corp. Reports on Advancement of Its Lung Cancer Drug Candidate L-DOS47
Marketwire Canada - Thu Mar 03, 6:21PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the Trial Steering Committee has completed a review of safety data and recommended the opening of patient screening for the sixteenth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland ("LDOS002"

.
HBP: 5.41 (-0.04), HBP.TO: 1.99 (+0.14)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

NARUTO Card Game Set for June 2027 Global Launch

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

AI Drives Major Time Savings in Endoscopy Tech

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...